Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects

被引:12
|
作者
Ooi, Esther M. M. [1 ]
Janus, Edward D. [2 ]
Grant, Susan J. [3 ]
Sinclair, Lucia M. T. [3 ]
Barrett, P. Hugh R. [1 ]
机构
[1] Univ Western Australia, Royal Perth Hosp, Sch Med & Pharmacol, Metab Res Ctr, Perth, WA 6009, Australia
[2] Univ Melbourne, Western Hosp, Dept Med, Footscray, Vic, Australia
[3] Princess Margaret Hosp, Christchurch 2, New Zealand
基金
英国医学研究理事会;
关键词
apoE2/E2; genotype; kinetics; Type III hyperlipidemia; INTERMEDIATE DENSITY LIPOPROTEINS; RECEPTOR-BINDING ACTIVITY; III HYPERLIPOPROTEINEMIA; FAMILIAL DYSBETALIPOPROTEINEMIA; B METABOLISM; ARTERY-DISEASE; PLASMA; VARIANT; ATHEROSCLEROSIS; HUMANS;
D O I
10.1194/jlr.M004705
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of apolipoprotein (apo) E genotype on apoB-100 metabolism was examined in three normolipidemic apoE2/E2, five type III hyperlipidemic apoE2/E2, and five hyperlipidemic apoE3/E2 subjects using simultaneous administration of I-131-VLDL and I-125-LDL, and multi-compartmental modeling. Compared with normolipidemic apoE2/E2 subjects, type III hyperlipidemic E2/E2 subjects had increased plasma and VLDL cholesterol, plasma and VLDL triglycerides, and VLDL and intermediate density lipoprotein (IDL) apoB concentrations (P < 0.05). These abnormalities were chiefly a consequence of decreased VLDL and IDL apoB fractional catabolic rate (FCR). Compared with hyperlipidemic E3/E2 subjects, type III hyperlipidemic E2/E2 subjects had increased IDL apoB concentration and decreased conversion of IDL to LDL particles (P < 0.05). In a pooled analysis, VLDL cholesterol was positively associated with VLDL and IDL apoB concentrations and the proportion of VLDL apoB in the slowly turning over VLDL pool, and was negatively associated with VLDL apoB FCR after adjusting for subject group. VLDL triglyceride was positively associated with VLDL apoB concentration and VLDL and IDL apoB production rates after adjusting for subject group. A defective apoE contributes to altered lipoprotein metabolism but is not sufficient to cause overt hyperlipidemia. Additional genetic mutations and environmental factors, including insulin resistance and obesity, may contribute to the development of type III hyperlipidemia. Ooi, E. M. M., E. D. Janus, S. J. Grant, L. M. T. Sinclair, and P. H. R. Barrett. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. J. Lipid Res. 2010. 51: 2413-2421.
引用
收藏
页码:2413 / 2421
页数:9
相关论文
共 50 条
  • [21] FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 - EFFECT OF SIMVASTATIN TREATMENT
    CORSINI, A
    MAZZOTTI, M
    GRANATA, A
    ROMANO, L
    ROMANO, C
    FUMAGALLI, R
    CATAPANO, AL
    ARTERIOSCLEROSIS, 1990, 10 (05): : A817 - A818
  • [22] DISTRIBUTION OF APOLIPOPROTEIN-E PHENOTYPES IN NORMOLIPIDEMIC AND HYPERLIPIDEMIC ITALIAN SUBJECTS AND IDENTIFICATION OF AN APO-E1 VARIANT
    GABELLI, C
    BAGGIO, G
    MARTINI, S
    BARBATO, GM
    CORTI, C
    CREPALDI, G
    ARTERIOSCLEROSIS, 1987, 7 (05): : A516 - A516
  • [23] Inhibition of cholesterogenesis decreases hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects
    Watts, GF
    Naoumova, RP
    Kelly, JM
    Riches, FM
    Croft, KD
    Thompson, GR
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 356 - 356
  • [24] APOLIPOPROTEIN-B SYNTHESIS IN HUMANS - LIVER SYNTHESIZES ONLY APOLIPOPROTEIN B-100
    EDGE, SB
    HOEG, JM
    SCHNEIDER, PD
    BREWER, HB
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (08): : 726 - 730
  • [25] Familial defective apolipoprotein B-100: A review
    Andersen, Lars H.
    Miserez, Andre R.
    Ahmad, Zahid
    Andersen, Rolf L.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (06) : 1297 - 1302
  • [26] Effects of a thyromimetic on apolipoprotein B-100 in rats
    Wada, Y
    Matsubara, S
    Dufresne, J
    Hargrove, GM
    Stephan, ZF
    Steele, RE
    Wong, NCW
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2000, 25 (03) : 299 - 308
  • [27] Kinetics of very-low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies
    Watts, GF
    Moroz, P
    Barrett, PHR
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (09): : 1204 - 1210
  • [28] Genetic determinants of apolipoprotein B-100 kinetics
    Ng, Theodore W. K.
    Ooi, Esther M. M.
    Watts, Gerald F.
    Chan, Dick C.
    Barrett, P. Hugh R.
    CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (02) : 141 - 147
  • [29] Reduction of lipid hydroperoxides by apolipoprotein B-100
    Mashima, R
    Yoshimura, S
    Yamamoto, Y
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 259 (01) : 185 - 189
  • [30] DEGRADATION OF APOLIPOPROTEIN B-100 IN HUMAN CHYLOMICRONS
    LEE, DM
    SINGH, S
    BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 960 (02) : 148 - 156